Pyrazinamide Resistance, Mycobacterium tuberculosis Lineage and Treatment Outcomes in San Francisco, California

Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteristics of PZA resistant tuberculosis. Using a retrospecti...

Full description

Saved in:

Bibliographic Details
Published in:	PloS one Vol. 9; no. 4; p. e95645
Main Authors:	Budzik, Jonathan M., Jarlsberg, Leah G., Higashi, Julie, Grinsdale, Jennifer, Hopewell, Phil C., Kato-Maeda, Midori, Nahid, Payam
Format:	Journal Article
Language:	English
Published:	United States Public Library of Science 01.04.2014 Public Library of Science (PLoS)
Subjects:	Antibiotics Antitubercular Agents - therapeutic use Biology and Life Sciences Clinical outcomes Comparative analysis Critical care Data processing Demographics Disease Disease resistance Drug resistance Drug resistance in microorganisms Drug therapy Epidemiology Health surveillance Hospitals Humans Infections Medical diagnosis Medicine Medicine and Health Sciences Microbial Sensitivity Tests Mycobacterium bovis Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - pathogenicity Patient outcomes Patients Pharmaceutical research Public health Pyrazinamide Pyrazinamide - pharmacology Pyrazinamide - therapeutic use Retrospective Studies San Francisco Statistical analysis Treatment Outcome Tuberculosis Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy San Francisco California Canada San Francisco California United States > US Quebec Canada
ISSN:	1932-6203, 1932-6203
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!